Connor, Clark & Lunn Investment Management (CC&L)’s Ultragenyx Pharmaceutical RARE Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.4M	Sell	191,578 -309,344	-62%	-$7.68M	0.01%	650
2026 Q1	$10.5M	Buy	500,922 +237,053	+90%	+$5.34M	0.02%	463
2025 Q4	$6.07M	Buy	263,869 +184,947	+234%	+$6.08M	0.02%	590
2025 Q3	$2.37M	Buy	78,922 +73,037	+1,241%	+$2.19M	0.01%	807
2025 Q2	$214K	Sell	5,885 -39,016	-87%	-$1.41M	﹤0.01%	1412
2025 Q1	$1.63M	Buy	44,901 +17,885	+66%	+$744K	0.01%	787
2024 Q4	$1.14M	Sell	27,016 -48,249	-64%	-$2.39M	0.01%	886
2024 Q3	$4.18M	Sell	75,265 -87,626	-54%	-$4.46M	0.02%	485
2024 Q2	$6.69M	Buy	162,891 +7,366	+5%	+$315K	0.03%	360
2024 Q1	$7.26M	Buy	155,525 +69,068	+80%	+$3.26M	0.03%	358
2023 Q4	$4.13M	Sell	86,457 -95,778	-53%	-$3.71M	0.02%	482
2023 Q3	$6.5M	Sell	182,235 -23,796	-12%	-$943K	0.03%	338
2023 Q2	$9.5M	Sell	206,031 -1,827	-0.9%	-$84.7K	0.05%	261
2023 Q1	$8.34M	Sell	207,858 -22,336	-10%	-$958K	0.05%	281
2022 Q4	$10.7M	Buy	230,194 +41,773	+22%	+$1.64M	0.06%	222
2022 Q3	$7.8M	Buy	188,421 +155,840	+478%	+$8.01M	0.05%	246
2022 Q2	$1.94M	Buy	+32,581	New	+$2M	0.01%	476
2021 Q3	–	Sell	-2,357	Closed	-$225K	–	1191
2021 Q2	$225K	Sell	2,357 -13,109	-85%	-$1.37M	﹤0.01%	900
2021 Q1	$1.76M	Buy	15,466 +12,840	+489%	+$1.75M	0.01%	588
2020 Q4	$364K	Buy	+2,626	New	+$312K	﹤0.01%	764
2015 Q3	–	Sell	-3,800	Closed	-$389K	–	779
2015 Q2	$389K	Sell	3,800 -1,500	-28%	-$116K	﹤0.01%	458
2015 Q1	$329K	Buy	+5,300	New	+$294K	﹤0.01%	446

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s RARE Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Ultragenyx Pharmaceutical (RARE) stake by 62% in Q2 2026, selling an estimated $7.68M and leaving 191,578 shares worth $6.4M. The position accounts for 0.01% of the portfolio, ranked #650.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in RARE in Q1 2015 and has held it in 22 quarters since. The position peaked at $10.7M in Q4 2022. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 191,578 shares of Ultragenyx Pharmaceutical worth $6.4M as of Q2 2026.
Connor, Clark & Lunn Investment Management (CC&L) sold 309,344 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $7.68M.
Ultragenyx Pharmaceutical made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #650 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 22 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s Ultragenyx Pharmaceutical position peaked at $10.7M in Q4 2022.
310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.